Literature DB >> 10708549

Effect of elcatonin on osteoinduction by recombinant human bone morphogenetic protein-2.

Y Okubo1, K Bessho, K Fujimura, K Kusumoto, Y Ogawa, T Iizuka.   

Abstract

To evaluate the effect of elcatonin on osteoinduction by recombinant human bone morphogenetic protein-2 (rhBMP-2), 5 microg of rhBMP-2 was implanted into intramuscular sites of rats. For 14 days after the implantation, elcatonin was administered intraperitoneally with total dosage of 80 U, 8 U, and 0.8 U, respectively. For the control group, only physiological saline was administered. At 21 days after implantation, the area of the oval shadow in the radiologic findings depended on the elcatonin dose and the amount of trabecular bone and the number of osteoblasts observed in the histologic findings depended on the dosage of elcatonin. The values of ALP activity and Ca content also showed an elcatonin dose dependency. These results suggested that elcatonin is effective in enhancing osteoinduction by rhBMP-2 within the dose range of this study, and that elcatonin has an anabolic effect on osteoblasts in addition to an antiresorptive effect. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708549     DOI: 10.1006/bbrc.2000.2294

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates.

Authors:  Huaizhong Pan; Monika Sima; Pavla Kopecková; Kuangshi Wu; Songqi Gao; Jihua Liu; Dong Wang; Scott C Miller; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2008-05-28       Impact factor: 4.939

2.  Bone Regeneration of Rat Calvarial Defect by Magnesium Calcium Phosphate Gelatin Scaffolds with or without Bone Morphogenetic Protein-2.

Authors:  Ahmed Hussain; Katsu Takahashi; Junya Sonobe; Yasuhiko Tabata; Kazuhisa Bessho
Journal:  J Maxillofac Oral Surg       Date:  2013-01-31

3.  Antibody-mediated "universal" osteoclast targeting platform using calcitonin as a model drug.

Authors:  Madhuri Newa; Krishna Hari Bhandari; Lili Tang; Rohit Kalvapalle; Mavanur Suresh; Michael R Doschak
Journal:  Pharm Res       Date:  2011-02-08       Impact factor: 4.200

4.  Accelerators of osteogenesis by recombinant human bone morphogenetic protein-2.

Authors:  Yasunori Okubo; Kenji Kusumoto; Kazuhisa Bessho
Journal:  Drug Target Insights       Date:  2007-02-21

5.  Molecular characterization and analysis of the porcine NURR1 gene.

Authors:  Knud Larsen; Jamal Momeni; Leila Farajzadeh; Henrik Callesen; Christian Bendixen
Journal:  Biochim Open       Date:  2016-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.